REMINDER: Our user survey closes on Friday, please submit your responses here.
Anyone in London going to the NSCI Proactive presentation next Thursday 6pm?
The opportunity to work with Eon on the Karbon Homes and other similar projects represents a significant milestone in Q-Bot’s growth. Eon are involved in roughly 20% of all UK Housing Retrofit Projects, and our close collaboration, which has developed through our early Energy Company Obligation (ECO) funding relationship show an exciting trajectory for our innovative underfloor insulation solution. Leigh Fairbrother, Q-Bot Head of Commercial
Q-Bot appointed by energy solutions provider E.ON to install measures to improve the efficiency of Otterburn homes
12 January 2023
Q-Bot has recently been appointed by energy solutions provider E.ON to install its robotic underfloor insulation in 34 properties in Otterburn in the North of England.
The homes are managed by Karbon Homes, which aims to get these properties close to net zero by installing several energy efficiency measures funded through the Social Housing Decarbonisation Fund wave 1.
Formed in 2017, Karbon Homes is a housing association in the North East of England and Yorkshire, managing almost 30,000 homes. They are focused on delivering good quality homes, excellent service to their customers, and creating a sustainable and friendly environment for their local communities.
Karbon Homes aims to drive the path to net zero homes by installing multiple energy efficiency measures. This will involve ensuring appropriate insulation coverage in lofts and increasing the thickness where required, installing external or cavity wall insulation, solar panels which will generate electricity for customers to use for free, and finally Q-Bot’s underfloor insulation.
Anthony Bell, Karbon’s Assistant Director of Asset and Regeneration said: “With the cost of energy rising fast, our work to improve the efficiency of our homes has never been more important. This significant investment, made possible thanks to support from our local authority partners, will reduce the energy demand from these 90 homes and in turn reduce carbon emissions.”
E.ON is the managing agent on behalf of Karbon Homes, acting as the Principal Contractor. E.ON is an energy provider of energy efficiency measures to social housing associations, local authorities, and private residential customers. The retrofit measures are usually financed through government funding such as the Local Authority Delivery Scheme, Social Housing Decarbonisation Fund and Energy Company Obligation. E.ON plays a key role in the retrofit sector, delivering 11 other similar upgrade schemes across the country.
Dave Newitt, Director of E.ON’s Energy Installation Services division, said: “We work with local authorities and housing associations across the country to improve the energy efficiency and sustainability of people’s homes and we’re delighted to be working with Q-Bot and Karbon Homes to improve the energy efficiency of homes across the Otterburn region.
By working with organisations such as the Karbon Homes, we’re able to utilise existing funding programmes through our Energy Company Obligation, to ensure residents can become more sustainable and benefit from lower energy bills and we can work together to support the UK’s net zero ambition.”
Q-Bot provides a unique method of installing underfloor insulation, fully recognised, and leveraged in the housing sector. Operating from its headquarters in London and with operational bases in New
In Person Event - Thursday 26th January 2023
You are warmly invited to participate in the Proactive ONE2ONE investor forum which is taking place on Thursday 26th January from 17:45 onwards at The Chesterfield Mayfair Hotel (35 Charles Street, Mayfair, London, W1J 5EB).
REGISTER
Presenting companies:
Mosman Oil and Gas LTD (LON:MSMN)
Roquefort Therapeutics PLC (LON:ROQ) is a biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
The company's portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.
Lavras Gold Corp (CVE:LGC)
NetScientific PLC (LON:1SN) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.
The company identifies, invests in, and builds high growth companies in the UK and internationally.
Canada Silver Works (CVE:CCW)
Scirocco Energy PLC (LON:SCIR) is an AIM investing company targeting attractive production and development opportunities within the European transition energy market.
Yellow Cake plc (LON:YCA)
CentralNic Group PLC (LON:CNIC) is the developer and operator of software platforms providing web presence services to customers in almost every country in the world.
Headquartered in London, the company is a leading provider of tools required to create websites, use email, and secure business online.
Twitter
LinkedIn
YouTube
Facebook
Instagram
This event is suitable for sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. The event is not suitable for people pursuing commercial opportunities Click here to unsubscribe.
Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, with Company Registration number 05639690. Group VAT registration number 872070825
Diepenbeek, Belgium, January 13th, 2023 – Fox BIOSYSTEMS announces today that
they successfully closed on their funding round, raising €5.8M in new capital. Investors in
this round are Heran Partners, LRM, The Gemma Frisius Fund, KU Leuven, and
NetScientific.
FOX BIOSYSTEMS has developed an innovative Surface Plasmon Resonance (SPR)
technology using optical sensors. Their product, the White FOx, combines a microfluidicsfree
dip-in protocol for fast and user friendly SPR sensing. The unique approach of the
White FOx eliminates the risk of clogging and cross-contamination when using complex
samples such as lysates, whole blood or large particles. The sensor probes are available
with several generic surface chemistries and can be switched easily to allow the detection
of different target molecules, including antibodies, nanobodies, microvesicles, phages and
large particles, all with a single lab device.
A wide range of applications make the White FOx the ideal option for any life science or
biopharmaceutical research lab. Kinetic affinity analysis, label free biomolecule
quantification and fast specific and ultra-sensitive sandwich assays are all possible and
uniquely facilitate analysis of complex unpurified samples.
The additional raised capital will be used to scale up the company’s operations, accelerate
the development of new application areas, and to boost the commercialization of this
unique system.
Thomas van Elzakker, CEO of FOx BIOSYSTEMS: “We are very happy with the strong
support of our investors for our highly motivated team in realizing our vision for FOx
BIOSYSTEMS. They are confidently investing in our fast commercial growth today, while
also enabling us to deliver on our exciting innovation roadmap for tomorrow. The White
FOx system offers a solution to many of today’s analysis challenges, and it will continue
to be key in revealing new data and helping scientists to reach their goals more quickly.”
Katleen Vandersmissen, PhD, Chair of FOx BIOSYSTEMS and Managing Partner of HERAN
Partners: “With HERAN we try to spot those technologies and teams that can make a
difference and positive impact within the domain of Life Sciences. We believe that FOx,
now strongly backed by this financing round and the recent EIC grant, is up for success
based on their innovative take and ease of use on complex samples.”
About FOx Biosystems
FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences
and pharmacological research market with innovative real-time, label-free analysis
products. The basis of their success is a novel fiber-optic-based SPR biosensor which
enables users to generate high-quality, cost-effective biomolecular data fast, and over a
wide range of applications.
For more information visit www.foxbiosystems.com
Contact:
Mr. Kris Ver Donck, VP Marketing & Applications
info@foxbiosystems.com
About Heran Partners
Heran Partners is a Belgian-based MedTech an
Have to say it is quite unbelievable that ProAxis still haven't updated their website with the 3/4 new products.
There was mention of a new site but shocking that with all the new hires and expansion they miss the basics.
Looks like ProAxis is finally ready to showcase itself.
JPMorgan Healthcare is the place to be and you might notice they now have offices in Rockville USA.
Looking forward to the annual update (last year 6th Jan)
ProAxsis
@ProAxsis
·
3h
Please email info@proaxsis.com to schedule a meeting at JPM, or for any other further information.
#healthcare #JPMconference #proteases #biomarkers #assaydevelopment #invitrodiagnostics #diseasemanagement #respiratorydisease #bonehealth
ProAxsis
@ProAxsis
·
Dec 14, 2022
Christmas is approaching so place your orders now for a timely delivery for Q1 or even sooner.
2022 saw our company grow with Head Office doubling in size and the launch of new key products.
We will continue to build on this with all our partners, current and new in 2023!
The warrants are priced at 8p and then 10p.
We had an annual update on the 6th Jan this year from ProAxis.
7 products for sale, doing funding rounds and want to expand into the USA.
Elephant in the room is their abysmal sales of £100K in the last accounts?!
Total radio silence from the BOD on our main investments doesn't help.
Lot's of pussed off share holders who got suckered in at £1.30 and a few at 67p which explains the drip of sales into any rise.
Proaxis have 7 products on the market but they can't be a*sed to update their website to tell anyone. In theory they are looking for outside investors but no idea how that is going.
QBot doing £10M a year run rate but who would know.
Glycotest, god only knows.
Anyway, in the September 22 results assets where £30M with PDSB making up £4M of that.
PDSB is now £14M so the other £26M is in the SP for free.
Ivan and his mate own 55% so maybe the silence is a plan to take private on the cheap?
Either way, we should be above a £1.00 after yesterdays excellent PDSB results.
When PDSB hits $1B market cap or approx $30 a share, our holding will have a cash value of £2.00 a share.
If positive PDSB trial results continue to come in and the FDA engages, there is no reason to believe this won't happen. Remember PDSB owns the whole platform.
The rest of the portfolio is worth another £1.00 a share.
Should be an interesting year!
That didn't take long.
Twitter on fire with PDSB and quite a few mentions of NSCI as a way in.
Massive volume of 3M and some really bullish option positions being taken.
Up 25% so NSCI now worth PDSB and cash.
The other £25M of assets in there for free.
One year into the court case and LG have kicked out the entire management team from Alphonso that got them into the sh@t in the first place!?
Pretty much handed the case to the Tremor team so i can't see it going to open court.
Just a question of how much we get and how soon?
Xmas email from QBot.
Note the 150 installations a month. Normal quote is more than £5K so we are looking at approx £10M T/O a year going forward!
Hope all is well with you.
On behalf of the Q-Bot team, we wish you and your team a very happy Christmas and New Year. We hope that you are able to spend some quality time with loved ones.
It's been a real pleasure working with you throughout 2022 (as always!), improving warmth in people’s home and tackling climate change. Q-Bot's underfloor insulation measure is now being installed in over 150 homes every month, and this number continues to grow. Q-Bot works with over 50 registered social providers, a network of accredited installers, managing agents and private homeowners to significantly reduce the demand for heat in domestic properties.
Thank you for all your support and your continued engagement. We hope to enjoy more of the same in 2023 and beyond.
Wishing you a great Christmas and a wonderful New Year.
With many thanks and festive wishes.
The Q-Bot Team
Thank you to
@Global_H_Pharma
who have awarded SageTech Medical the title of 'Most Environmentally-Conscious #Medical Technology Developer' in their 2023 Global Excellence Awards!
You can see our listing here:
https://ghp-news.com/issues/q4-2022/64/
#GHP #anaesthesia #sustainable
The last scoop took us to £5.50 before we rapidly fell back to earth.
Kleinman is Toscas go to leak man so the level of detail is probably correct.
Interesting focus on NewsCorp this time round.
GS want fees and Tosca need a better end of year/qtr price to cover their books.
Let's hope a name comes forward.
Good effort FlagStaff.
Now see if you can find some new investors?
A couple of things happened today.
PDSB almost hit $10 on a second day of high volume. Rumour that the FDA is going to fast track our lead trial.
Now worth £11.5M of our £14.5M MCap!
Netscientific have a new website! (first time i've seen it anyway)
and today's tweet.
Our portfolio company @FOxBIOSYSTEMS has been awarded €2.5 million @EUeic grant to accelerate the market introduction of unique Extracellular Vesicle (EV) analysis and isolation application.
Proaxis tweeting about the launch of 'K-Postn' which is the product deal they did with Uni of Geneva.
Assume one of the 7 products they now have for sale from the recent interview.
Very good news, if a bit delayed!
ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
FEBRUARY 21, 2021-POSTED BY DAVID RIBEIRO
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of Geneva and the University Hospital of Geneva, today announce that they have reached agreement on a global licensing agreement. Researchers at the University have developed a highly novel assay for a Cathepsin K-dependent periostin cleavage product, as a biomarker of bone fragility related to disorders such as osteoporosis. The technology is currently the subject of patent applications in Europe and the US. As a result of this agreement, ProAxsis will complete the technical validation of the assay, and seek to commercialise the assay in key territories before the end of 2021.
Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:
“We believe this assay will allow the rapid non-invasive identification of subjects at high risk of osteoporotic fractures and potentially other metabolic bone diseases. This is an incredibly exciting addition to our product portfolio and fits with our business growth plans; including identifying and in-licensing diagnostic tools which fulfil a high unmet need.”
Professor Serge Ferrari, Head of Bone Diseases at the University of Geneva and one of the inventors of the assay technology, said:
“Fragility fractures are a major clinical and public health issue, yet identification of subjects at high risk of fracture remains challenging. The high specificity of the Cathepsin K digested periostin fragment for bone thus presents itself as an ideal candidate to improve prediction of bone fragility.”
Dr Jennifer Cadby, Licensing Officer at the University of Geneva, added:
“We’re delighted to have signed this agreement with ProAxsis and are excited to combine the expertise of the groups in Geneva and Belfast.”
Any enquiries concerning ProAxsis’ product portfolio can be directed to info@proaxsis.com. For further information on the University of Geneva, please visit www.unige.ch
About ProAxsis
ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE level
The VIDAA deal is beginning to look pretty good.
One thing I missed was the $25M is an 'equity investment' in that do we now hold a $25M stake in VIDAA. If VIDAA goes on to be highly successful and IPO's in a few years time will we see a 2x/3X return?
At first I thought we had paid $25M for a long license and that cash was gone, but re-reading the text it's not the case?
Would be interesting to get some clarity from the company one day never.
18 August 2022
Tremor International Ltd
("Tremor" or the "Company")
Tremor International Announces Closing of $25 Million Strategic Investment in VIDAA
Tremor International Ltd. (AIM/NASDAQ: TRMR) ("Tremor" or the "Company"), a global leader in Video, Data, and Connected TV ("CTV") advertising offering an end-to-end technology platform that enables advertisers to optimize their campaigns and media partners to maximize yield on their digital advertising inventory, today announces the closing of its previously announced $25 million equity investment in VIDAA (the "Investment"), which was satisfied through existing cash resources.
VIDAA is a smart TV operating system and streaming platform, and a subsidiary of Hisense Co., Ltd. In connection with the Investment Tremor has also extended, for multiple years, its exclusive agreement to share VIDAA's automatic content recognition ("ACR") data for global measurement and targeting across the Company's end-to-end platform. VIDAA has also granted exclusivity in the US, UK, Canada, and Australia to the Unruly SSP and Spearad ad server, which was already designated as its preferred monetization platform globally. VIDAA is expected to utilize the Investment to support its plan to increase its distribution across additional OEMs, with the goal to grow global reach in key markets such as the US, UK, Canada, Germany, Japan, and Australia, as well as others.